Payment overview · 2025
General Payments
$181.96
11 reported records · 8 companies
Healthcare provider profile · identity verified
Zachariah E. Tempelmeyer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TECUMSEH, NE · NPI 1487660601
Verified facts
What the public records show
CMS Open Payments records show Zachariah E. Tempelmeyer, M.D. received $181.96 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexium by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.04 | 19.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.67 | 17.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.00 | 17.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.80 | 13.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.49 | 8.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.84 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.73 | 8.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.39 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.96 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 51 |
| Losartan Potassium | Losartan Potassium | 197 | 44 |
| Furosemide | Furosemide | 196 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 46 |
| Tramadol Hcl | Tramadol Hcl | 160 | 40 |
| Eliquis | Apixaban | 157 | 18 |
| Omeprazole | Omeprazole | 157 | 42 |
| Potassium Chloride | Potassium Chloride | 152 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 38 |
| Lisinopril | Lisinopril | 149 | 40 |
| Prednisone | Prednisone | 145 | 74 |
| Gabapentin | Gabapentin | 133 | 36 |
| Carvedilol | Carvedilol | 111 | 24 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 25 |
| Celecoxib | Celecoxib | 101 | 22 |
| Trazodone Hcl | Trazodone Hcl | 99 | 13 |
| Myrbetriq | Mirabegron | 96 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 26 |
| Donepezil Hcl | Donepezil Hcl | 87 | 14 |
| Jardiance | Empagliflozin | 86 | 16 |
| Simvastatin | Simvastatin | 86 | 19 |
| Montelukast Sodium | Montelukast Sodium | 85 | 21 |
| Xarelto | Rivaroxaban | 84 | 14 |
| Memantine Hcl | Memantine Hcl | 83 | suppressed |
| Mounjaro | Tirzepatide | 82 | 14 |
| Meloxicam | Meloxicam | 80 | 26 |
| Mirtazapine | Mirtazapine | 78 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 19 |
| Sertraline Hcl | Sertraline Hcl | 72 | 21 |
| Alprazolam | Alprazolam | 70 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 14 |
| Allopurinol | Allopurinol | 64 | 21 |
| Spironolactone | Spironolactone | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 13 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Finasteride | Finasteride | 45 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Torsemide | Torsemide | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Estradiol | Estradiol | 37 | 12 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 17 |
| Ondansetron Odt | Ondansetron | 35 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 32 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Multaq | Dronedarone Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 19 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Phenytoin | Phenytoin | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lexapro | Escitalopram Oxalate | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.96 · 11 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, EVENITY, LEQVIO, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error